BR112022020871A2 - Agentes imunoestimuladores em combinação com inibidores da angiogênese - Google Patents
Agentes imunoestimuladores em combinação com inibidores da angiogêneseInfo
- Publication number
- BR112022020871A2 BR112022020871A2 BR112022020871A BR112022020871A BR112022020871A2 BR 112022020871 A2 BR112022020871 A2 BR 112022020871A2 BR 112022020871 A BR112022020871 A BR 112022020871A BR 112022020871 A BR112022020871 A BR 112022020871A BR 112022020871 A2 BR112022020871 A2 BR 112022020871A2
- Authority
- BR
- Brazil
- Prior art keywords
- combination
- angiogenesis inhibitors
- immunostimulatory agents
- patient
- angiogenesis
- Prior art date
Links
- 229940121369 angiogenesis inhibitor Drugs 0.000 title abstract 3
- 239000004037 angiogenesis inhibitor Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title abstract 2
- 230000003308 immunostimulating effect Effects 0.000 title abstract 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 abstract 1
- 229960003784 lenvatinib Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
AGENTES IMUNOESTIMULADORES EM COMBINAÇÃO COM INIBIDORES DA ANGIOGÊNESE. A invenção fornece composições e métodos para tratar câncer em um paciente com uma terapia de combinação compreendendo administrar ao paciente uma proteína de fusão de SEQ ID NO: 1, em combinação com um inibidor de angiogênese (por exemplo, um anticorpo anti-VEGF ou lenvatinibe).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063010185P | 2020-04-15 | 2020-04-15 | |
US202163165391P | 2021-03-24 | 2021-03-24 | |
PCT/US2021/027503 WO2021211857A1 (en) | 2020-04-15 | 2021-04-15 | Immunostimulatory agents in combination with angiogenesis inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022020871A2 true BR112022020871A2 (pt) | 2023-04-11 |
Family
ID=78083724
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022020871A BR112022020871A2 (pt) | 2020-04-15 | 2021-04-15 | Agentes imunoestimuladores em combinação com inibidores da angiogênese |
Country Status (11)
Country | Link |
---|---|
US (2) | US11834483B2 (pt) |
EP (1) | EP4135748A4 (pt) |
JP (1) | JP2023526743A (pt) |
KR (1) | KR20230016178A (pt) |
CN (1) | CN115697376A (pt) |
AU (1) | AU2021257874A1 (pt) |
BR (1) | BR112022020871A2 (pt) |
CA (1) | CA3175580A1 (pt) |
IL (1) | IL297279A (pt) |
MX (1) | MX2022012983A (pt) |
WO (1) | WO2021211857A1 (pt) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012154935A1 (en) * | 2011-05-12 | 2012-11-15 | Eisai R&D Management Co., Ltd. | Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof |
WO2013177187A2 (en) * | 2012-05-22 | 2013-11-28 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents |
DK2859015T3 (en) * | 2012-06-08 | 2018-06-18 | Alkermes Inc | LIGANDS MODIFIED BY CIRCULAR MODIFICATION AS AGONISTS AND ANTAGONISTS |
CA3086199A1 (en) * | 2017-12-19 | 2019-06-27 | Xencor, Inc. | Engineered il-2 fc fusion proteins |
WO2020036635A2 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
WO2020146773A1 (en) | 2019-01-11 | 2020-07-16 | University Of Miami | Methods of using il-2/cd25 fusion protein |
US20210038684A1 (en) * | 2019-06-11 | 2021-02-11 | Alkermes Pharma Ireland Limited | Compositions and Methods for Cancer Immunotherapy |
CN114555110A (zh) * | 2019-10-18 | 2022-05-27 | 奥克梅斯制药爱尔兰有限公司 | 与免疫检查点抑制剂组合的免疫调节性il-2剂 |
-
2021
- 2021-04-15 BR BR112022020871A patent/BR112022020871A2/pt not_active Application Discontinuation
- 2021-04-15 JP JP2022562837A patent/JP2023526743A/ja active Pending
- 2021-04-15 MX MX2022012983A patent/MX2022012983A/es unknown
- 2021-04-15 WO PCT/US2021/027503 patent/WO2021211857A1/en unknown
- 2021-04-15 EP EP21788817.1A patent/EP4135748A4/en active Pending
- 2021-04-15 US US17/231,309 patent/US11834483B2/en active Active
- 2021-04-15 CN CN202180042246.3A patent/CN115697376A/zh active Pending
- 2021-04-15 AU AU2021257874A patent/AU2021257874A1/en active Pending
- 2021-04-15 KR KR1020227039974A patent/KR20230016178A/ko unknown
- 2021-04-15 IL IL297279A patent/IL297279A/en unknown
- 2021-04-15 CA CA3175580A patent/CA3175580A1/en active Pending
-
2023
- 2023-10-23 US US18/492,141 patent/US20240158454A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230016178A (ko) | 2023-02-01 |
CN115697376A (zh) | 2023-02-03 |
EP4135748A1 (en) | 2023-02-22 |
MX2022012983A (es) | 2023-01-18 |
US11834483B2 (en) | 2023-12-05 |
JP2023526743A (ja) | 2023-06-23 |
EP4135748A4 (en) | 2024-06-19 |
US20210347837A1 (en) | 2021-11-11 |
WO2021211857A1 (en) | 2021-10-21 |
US20240158454A1 (en) | 2024-05-16 |
AU2021257874A1 (en) | 2022-11-17 |
CA3175580A1 (en) | 2021-10-21 |
IL297279A (en) | 2022-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022009460A (es) | Vacuna contra el coronavirus. | |
BR112021000807A8 (pt) | Usos de um polipeptídeo da enzima de degradação de imunoglobulina g, uso de uma sequência de ácido nucleico, uso de um vetor de expressão, embalagem ou kit e uso de uma embalagem ou kit | |
BR112022007158A2 (pt) | Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico | |
WO2020093006A8 (en) | Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7) | |
MX2023007574A (es) | "vacuna de arn contra variantes de sars-cov-2. | |
MX2021015753A (es) | Constructo de arn. | |
BR112021017375A2 (pt) | Composição farmacêutica combinando método imunológico e quimioterapêutico para o tratamento de câncer | |
CR20220618A (es) | Nuevas proteinas de unión a repeticiones de anquirina y sus usos | |
CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
MX2023002330A (es) | Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos. | |
MX2022009100A (es) | Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer. | |
BR112022014552A2 (pt) | Polipeptídeo recombinante, composição farmacêutica, método de prevenção ou tratamento de uma infecção viral em um indivíduo que necessita do mesmo, molécula de rna, composição terapêutica, sistema de expressão, polipeptídeo recombinante para tratar infecção por sars-cov-2 e polinucleotídeo que codifica o polipeptídeo recombinante | |
BR112022008653A2 (pt) | Conjugado anticorpo-fármaco, método para tratar câncer, e, uso do conjugado anticorpo-fármaco | |
BR112019011350A2 (pt) | terapia de combinação | |
ZA202110285B (en) | Antibodies and methods of use | |
BR112023022774A2 (pt) | Terapias de combinação para tratamento de câncer | |
BR112020004935A2 (pt) | Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular | |
BR112022012081A2 (pt) | Método para tratar câncer, kit, e, uso de uma combinação terapêutica | |
BR112022020871A2 (pt) | Agentes imunoestimuladores em combinação com inibidores da angiogênese | |
WO2021158755A3 (en) | Leptospiral proteins and uses thereof | |
PE20221663A1 (es) | Composicion para prevenir o tratar enfermedades pulmonares que comprende proteina 1 de union de hialuronano y proteoglucano | |
BR112022020846A2 (pt) | Agentes imunoestimuladores em combinação com inibidores de angiogênese | |
MX2021013426A (es) | Tratamiento de la cefalea usando anticuerpos anti-cgrp. | |
CL2023000121A1 (es) | Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrófilas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing |